Janone technologies announces closing of registered direct offering of common stock priced at-the-market

Las vegas , march 24, 2023 /prnewswire/ -- janone (nasdaq: jan), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced the closing of its previously announced registered direct offering of 361,000 shares of the company's common stock at a purchase price of $1.17 per share of common stock priced at-the-market under nasdaq rules. h.c. wainwright & co. acted as the exclusive placement agent for the offering.
JAN Ratings Summary
JAN Quant Ranking